[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, Suh N, Yang CS, Minden A: The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res; 2008 Jul;6(7):1215-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Pak4 is expressed at low levels in most adult tissues, it is highly overexpressed in tumor cell lines.
  • Here, we show that Pak4 is also overexpressed in primary tumors, including colon, esophageal, and mammary tumors.
  • Furthermore, these results show for the first time that not only constitutively active Pak4, but also wild-type Pak4, is transforming, when experimental animals are used.
  • These results are highly significant because wild-type Pak4, rather than activated Pak4, is overexpressed in tumor cells.
  • The finding that Pak4 is up-regulated in so many types of cancers indicates that Pak4 may play a vital role in a wide range of different types of cancer.
  • This makes it an attractive candidate for drug therapy for different types of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1997 Oct 1;7(10):794-7 [9368762.001]
  • [Cites] Mol Cell Biol. 1997 Jun;17(6):3449-58 [9154844.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6527-40 [9822598.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23633-41 [10438546.001]
  • [Cites] Trends Biochem Sci. 1999 Sep;24(9):350-5 [10470034.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):615-22 [15703815.001]
  • [Cites] Ultrasound Med Biol. 2005 Jun;31(6):865-70 [15936502.001]
  • [Cites] J Intern Med. 2005 Dec;258(6):479-517 [16313474.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41192-200 [16227624.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):453-61 [10611223.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9106-9 [10734042.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3523-33 [11313478.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14414-9 [11278822.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8085-8 [11719432.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):550-8 [11668177.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jul;34(7):713-7 [11950587.001]
  • [Cites] Oncogene. 2003 Feb 20;22(7):1045-56 [12592391.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22374-8 [12686550.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7122-33 [14517283.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7838-48 [14560027.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):409-20 [14973385.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Aug;30(8):857-62 [9744077.001]
  • (PMID = 18644984.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / NIH R01 CA076342; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NCI NIH HHS / CA / R01 CA076342; United States / NCI NIH HHS / CA / CA076342-06A2; United States / NCI NIH HHS / CA / R01 CA076342-06A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / Pak4 protein, mouse; EC 2.7.11.1 / p21-Activated Kinases; EC 3.4.22.- / Caspase 3; EC 3.6.5.2 / Oncogene Protein p21(ras); EC 3.6.5.2 / cdc42 GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS175961; NLM/ PMC2822623
  •  go-up   go-down


2. Liu F, Wang JG, Wang SY, Li Y, Wu YP, Xi SM: Antitumor effect and mechanism of Gecko on human esophageal carcinoma cell lines in vitro and xenografted sarcoma 180 in Kunming mice. World J Gastroenterol; 2008 Jul 7;14(25):3990-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effect and mechanism of Gecko on human esophageal carcinoma cell lines in vitro and xenografted sarcoma 180 in Kunming mice.
  • AIM: To investigate the anti-tumor effect of Chinese medicine Gecko on human esophageal carcinoma cell lines and xenografted sarcoma 180 in Kunming mice and its mechanism.
  • METHODS: The serum pharmacological method was used in vitro.
  • The growth rates of the human esophageal carcinoma cells (EC9706 or EC1) were measured by a modified 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
  • The transplanted tumor model of the mouse S180 sarcoma was established.
  • After 2 wk of treatment, the anti-tumor activity was evaluated by tumor tissue weighing.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Esophageal Neoplasms / pathology. Lizards. Medicine, Chinese Traditional. Sarcoma 180 / drug therapy
  • [MeSH-minor] Administration, Oral. Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Down-Regulation. Female. Fibroblast Growth Factor 2 / metabolism. Humans. Mice. Rats. Rats, Sprague-Dawley. Spleen / drug effects. Thymus Gland / drug effects. Time Factors. Vascular Endothelial Growth Factor A / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Tohoku J Exp Med. 2007 Oct;213(2):139-48 [17917407.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] J Ethnopharmacol. 1987 Sep-Oct;21(1):45-53 [3695555.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):939-45 [7961123.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 Oct;24(10):919-21 [15553828.001]
  • [Cites] Ai Zheng. 2005 Dec;24(12):1459-63 [16351792.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Jan;26(1):58-62 [16466175.001]
  • [Cites] Chin J Integr Med. 2006 Mar;12(1):75-80 [16571292.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Aug;26(8):759-63 [16970106.001]
  • [Cites] World J Gastroenterol. 2006 Sep 28;12(36):5780-6 [17007042.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6766-70 [17106923.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Feb;27(2):178-81 [17343011.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2007 Feb;32(3):238-41 [17432148.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2007 Feb;32(4):281-4 [17455456.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jul;27(7):1027-9 [17666344.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • (PMID = 18609682.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC2725337
  •  go-up   go-down


3. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M: Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis; 2009 Apr 15;48(8):1138-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
  • BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy.
  • METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy.
  • Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy.
  • The most common ADEs were esophageal candidiasis (in 360 patients), Pneumocystis jiroveci pneumonia (320 patients), and Kaposi sarcoma (308 patients).
  • CONCLUSIONS: In the combination antiretroviral therapy era, mortality rates subsequent to an ADE depend on the specific diagnosis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 13;360(9327):119-29 [12126821.001]
  • [Cites] JAMA. 2003 May 21;289(19):2554-9 [12759327.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):180-9 [15249567.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1425-31 [6272109.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] JAMA. 1987 Sep 4;258(9):1143-5, 1149, 1153-4 [3041060.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):184-9 [1676252.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(10):1059-71 [1890600.001]
  • [Cites] JAMA. 1992 Nov 18;268(19):2662-6 [1359163.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] BMJ. 1994 Apr 23;308(6936):1068-73 [7909698.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2107-25 [7846414.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Arch Intern Med. 1995 Jul 24;155(14):1537-42 [7605156.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] AIDS. 1998 Jan 1;12(1):29-33 [9456252.001]
  • [Cites] Nat Med. 1998 Feb;4(2):208-14 [9461195.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] Infection. 2005 Feb;33(1):43-5 [15750761.001]
  • [Cites] BMJ. 2005 Mar 12;330(7491):594-6 [15761002.001]
  • [Cites] J Infect Dis. 2005 Sep 15;192(6):992-1002 [16107951.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):817-24 [16530575.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] AIDS. 2007 May 31;21(9):1185-97 [17502729.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1867-75 [17721094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] J Infect Dis. 2002 Jan 15;185(2):178-87 [11807691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95 [11917244.001]
  • (PMID = 19275498.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA013566-08; United States / NIAAA NIH HHS / AA / U10 AA013566; United Kingdom / Medical Research Council / / G0700820; United States / NIAAA NIH HHS / AA / U10 AA013566-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS264818; NLM/ PMC3032444
  • [Investigator] Casabona J; Chêne G; Costagliola D; Dabis F; D'Arminio Monforte A; de Wolf F; Egger M; Fatkenheuer G; Gill J; Hogg R; Justice A; Kitahata M; Ledergerber B; Mocroft A; Phillips A; Reiss P; Saag M; Sabin C; Staszewski S; Weller I; May M; Harris R; Sterne J; Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Guiguet M; Kousignian I; Lanoy E; Lièvre L; Potard V; Selinger-Leneman H; Bouvet E; Crickx B; Ecobichon JL; Leport C; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Roudière L; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit P; Desplanque N; Meyohas MC; Picard O; Cadranel J; Mayaud C; Bricaire F; Herson S; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Trepo C; Ravaux I; Delmont JP; Moreau J; Gastaut JA; Retornaz F; Soubeyrand J; Allegre T; Blanc PA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; May T; Rabaud C; Raffi F; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Yasdanpanah Y; Pradinaud R; Sobesky M; Contant M; Montroni M; Scalise G; Braschi MC; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Arici C; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Cosco L; Scerbo A; Vecchiet J; D'Alessandro M; Santoro D; Pusterla L; Carnevale G; Lorenzotti S; Viganò P; Mena M; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Grima P; Grima PF; Pagano G; Cassola G; Alessandrini A; Piscopo R; Toti M; Trezzi M; Soscia F; Tacconi L; Orani A; Perini P; Scasso A; Vincenti A; Chiodera F; Castelli P; Scalzini A; Palvarini L; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Cicconi P; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Abrescia N; Chirianni A; Izzo CM; Piazza M; De Marco M; Viglietti R; Manzillo E; Nappa S; Colomba A; Abbadessa V; Prestileo T; Mancuso S; Ferrari C; Pizzaferri P; Filice G; Minoli L; Bruno R; Novati S; Baldelli F; Camanni G; Petrelli E; Cioppi A; Alberici F; Ruggieri A; Menichetti F; Martinelli C; De Stefano C; La Gala A; Ballardini G; Rizzo E; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Dianzani F; Ippolito G; Antinori A; Antonucci G; Ciardi M; Narciso P; Petrosillo N; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Noto P; Lichtner M; Capobianchi MR; Carletti F; Girardi E; Pezzotti P; Rezza G; Mura MS; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Grossi PA; Basilico C; Poggio A; Bottari G; Raise E; Ebo F; Pellizzer G; Buonfrate D; Resta F; Loso K; Cozzi Lepri A; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Gorgievski M; Günthard H; Hirsch H; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Martinetti G; Martinez B; Müller N; Nadal D; Opravil M; Paccaud F; Pantaleo G; Rickenbach M; Rudin C; Schmid P; Schultze D; Schüpbach J; Speck R; Taffé P; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S; Gras LA; van Sighem AI; Smit C; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Branger J; Eeftinck Schattenkerk JK; Gisolf J; Godfried MH; Lange JM; Lettinga KD; van der Meer JT; Nellen FJ; van der Poll T; Ruys TA; Steingrover R; Vermeulen JN; Vrouenraets SM; van Vugt M; Wit FW; Kuijpers TW; Pajkrt D; Scherpbier HJ; van Eeden A; Brinkman K; van den Berk GE; Blok WL; Frissen PH; Roos JC; Schouten WE; Mulder JW; van Gorp EC; Wagenaar J; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen MG; Richter C; van der Berg J; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Pogány K; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; van Assen S; van Leeuwen JT; Doedens R; Scholvinck EH; ten Kate RW; Soetekouw R; van Houte D; Polée MB; Kroon FP; van den Broek PJ; van Dissel JT; Schippers EF; Schreij G; van der Geest S; Lowe S; Verbon A; Koopmans PP; Van Crevel R; de Groot R; Keuter M; Post F; van der Ven AJ; Warris A; van der Ende ME; Gyssens IC; van der Feltz M; Nouwen JL; Rijnders BJ; de Vries TE; Driessen G; van der Flier M; Hartwig NG; Juttman JR; van Kasteren ME; Van de Heul C; Hoepelman IM; Schneider MM; Bonten MJ; Borleffs JC; Ellerbroek PM; Jaspers CA; Mudrikove T; Schurink CA; Gisolf EH; Geelen SP; Wolfs TF; Faber T; Tanis AA; Groeneveld PH; den Hollander JG; Duits AJ; Winkel K; Back NK; Bakker ME; Berkhout B; Jurriaans S; Zaaijer HL; Cuijpers T; Rietra PJ; Roozendaal KJ; Pauw W; van Zanten AP; Smits PH; von Blomberg BM; Savelkoul P; Pettersson A; Swanink CM; Franck PF; Lampe AS; Jansen CL; Hendriks R; Benne CA; Veenendaal D; Storm H; Weel J; van Zeijl JH; Kroes AC; Claas HC; Bruggeman CA; Goossens VJ; Galama JM; Melchers WJ; Poort YA; Doornum GJ; Niesters MG; Osterhaus AD; Schutten M; Buiting AG; Swaans CA; Boucher CA; Schuurman R; Boel E; Jansz AF; Veldkamp A; Beijnen JH; Huitema AD; Burger DM; Hugen PW; van Kan HJ; Losso M; Duran A; Vetter N; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Lundgren J; Benfield T; Kirk O; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Oestergaard L; Zilmer K; Ristola M; Girard PM; Vanhems P; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Bogner J; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambattakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Mazeu I; Pristera R; Gabbuti A; Montesarchio E; Gargiulo M; Iacomi F; Vlassi C; Finazzi R; Galli M; Ridolfo A; Rozentale B; Aldins P; Chaplinskas S; Hemmer R; Staub T; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Clotet B; Jou A; Conejero J; Tural C; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Boffi E; Kravchenko E; Chentsova N; Barton S; Johnson AM; Mercey D; Johnson MA; Murphy M; Weber J; Scullard G; Fisher M; Brettle R; Gatell J; Gazzard B; Friis-Møller N; Bannister W; Ellefson M; Borch A; Podlekareva D; Holkmann Olsen C; Kjaer J; Peters L; Reekie J; Raffanti S; Dieterch D; Becker S; Scarsella A; Fusco G; Most B; Balu R; Rana R; Beckerman R; Ising T; Fusco J; Irek R; Johnson B; Hirani A; DeJesus E; Pierone G; Lackey P; Irek C; Johnson A; Burdick J; Leon S; Arch J; Helm EB; Carlebach A; Müller A; Haberl A; Nisius G; Lennemann T; Stephan C; Bickel M; Mösch M; Gute P; Locher L; Lutz T; Klauke S; Knecht G; Khaykin P; Doerr HW; Stürmer M; Babacan E; von Hentig N; Beylot J; Dupon M; Longy-Boursier M; Pellegrin JL; Ragnaud JM; Salamon R; Thiébaut R; Lewden C; Lawson-Ayayi S; Dupon M; Mercié P; Moreau JF; Morlat P; Bernard N; Lacoste D; Malvy D; Neau D; Blaizeau MJ; Decoin M; Delveaux S; Hannapier C; Labarrère S; Lavignolle-Aurillac V; Uwamaliya-Nziyumvira B; Palmer G; Touchard D; Balestre E; Alioum A; Jacqmin-Gadda H; Bonarek M; Bonnet F; Coadou B; Gellie P; Nouts C; Bocquentin F; Dutronc H; Lafarie S; Aslan A; Pistonne T; Thibaut P; Vatan R; Chambon D; De La Taille C; Cazorla C; Ocho A; Viallard JF; Caubet O; Cipriano C; Lazaro E; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Breilh D; Blanco P; Loste P; Caunègre L; Bonnal F; Farbos S; Ferrand M; Ceccaldi J; Tchamgoué S; De Witte S; Buy E; Alexander C; Barrios R; Braitstein P; Brumme Z; Chan K; Cote H; Gataric N; Geller J; Guillemi S; Harrigan PR; Harris M; Joy R; Levy A; Montaner J; Montessori V; Palepu A; Phillips E; Phillips P; Press N; Tyndall M; Wood E; Yip B; Bhagani S; Breen R; Byrne P; Carroll A; Cuthbertson Z; Dunleavy A; Geretti AM; Heelan B; Johnson M; Kinloch-de Loes S; Lipman M; Madge S; Marshall N; Nair D; Nebbia G; Prinz B; Shah S; Swader L; Tyrer M; Youle M; Chaloner C; Grabowska H; Holloway J; Puradiredja J; Ransom D; Tsintas R; Bansi L; Fox Z; Harris E; Hill T; Lampe F; Lodwick R; Smith C; Amoah E; Booth C; Clewley G; Garcia Diaz A; Gregory B; Janossy G; Labbett W; Thomas M; Read R; Krentz H; Beckthold B; Schmeisser N; Alquézar A; Esteve A; Podzamczer D; Murillas J; Romero A; Agustí C; Agüero F; Ferrer E; Riera M; Segura F; Navarro G; Force L; Vilaró J; Masabeu A; García I; Guadarrama M; Montoliu A; Ortega N; Lazzari E; Puchol E; Sanchez M; Blanco JL; Garcia-Alcaide F; Martinez E; Mallolas J; López-Dieguez M; García-Goez JF; Sirera G; Romeu J; Negredo E; Miranda C; Capitan MC; Olmo M; Barragan P; Saumoy M; Bolao F; Cabellos C; Peña C; Sala M; Cervantes M; Jose Amengual M; Navarro M; Penelo E; Barrufet P; Raper JL; Mugavero MJ; Willig JH; Schumacher J; Chang PW; Westfall AO; Cloud G; Lin HY; Acosta EP; Colette-Kempf M; Allison JJ; Pisu M
  •  go-up   go-down


Advertisement
4. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res; 2005 Apr 15;11(8):2785-808
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
  • 2-[(18)F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect.
  • However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response.
  • In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy.
  • Moreover, a reduction in the FDG-PET signal within days or weeks of initiating therapy (e.g., in lymphoma, non-small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now used in drug approvals.
  • These findings suggest that FDG-PET could facilitate drug development as an early surrogate of clinical benefit.
  • Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed.
  • Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837727.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 274
  •  go-up   go-down


5. Ranen E, Shamir MH, Shahar R, Johnston DE: Partial esophagectomy with single layer closure for treatment of esophageal sarcomas in 6 dogs. Vet Surg; 2004 Jul-Aug;33(4):428-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial esophagectomy with single layer closure for treatment of esophageal sarcomas in 6 dogs.
  • OBJECTIVE: To report partial esophagectomy (PE) as a treatment for esophageal sarcoma in dogs.
  • ANIMALS: Six dogs with caudal thoracic esophageal tumors.
  • METHODS: Medical records of 6 dogs that had surgical removal of esophageal tumors were reviewed.
  • Signalment, medical history, physical examination results, complete blood count, surgical procedure, tumor classification, postoperative treatment, and complications were retrieved.
  • RESULTS: Esophageal masses were approached by thoracotomy and esophagotomy on the side opposite the mass, removed with 1 cm margins by full thickness excision, and the defects closed with a single layer of interrupted sutures.
  • Tumors were fibrosarcoma (3 dogs), undifferentiated sarcoma (1), and osteosarcoma (2).
  • Five dogs were administered doxorubicin chemotherapy after surgery.
  • CONCLUSIONS: Partial esophagectomy and closure using 1 suture layer, was an effective, simple, and safe technique for removal of sarcomas of the distal thoracic esophagus.
  • CLINICAL RELEVANCE: Removal of esophageal masses by partial esophagectomy can be used reliably as a method of esophageal surgery.
  • [MeSH-major] Dog Diseases / epidemiology. Dog Diseases / surgery. Esophageal Neoplasms / veterinary. Esophagectomy / veterinary. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15230849.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Weber WA, Wieder H: Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging; 2006 Jul;33 Suppl 1:27-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring chemotherapy and radiotherapy of solid tumors.
  • The clinical value of FDG-PET for differentiation of residual or recurrent viable tumor and therapy-induced fibrosis or scar tissue has been documented for various solid tumors.
  • Furthermore, there are now several reports suggesting that quantitative assessment of therapy-induced changes in tumor FDG uptake may allow prediction of tumor response and patient outcome very early in the course of therapy.
  • In nonresponding patients, treatment may be adjusted according to the individual chemo- and radiosensitivity of the tumor tissue.
  • Since the number of alternative treatments for solid tumors (e.g., second-line chemotherapy agents, protein kinase, or angiogenesis inhibitors) is continuously increasing, early prediction of tumor response to chemotherapy and radiotherapy by FDG-PET has enormous potential to "personalize" treatment and to reduce the side-effects and costs of ineffective therapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Esophageal Neoplasms / diagnostic imaging. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Female. Head and Neck Neoplasms / diagnostic imaging. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Monitoring, Physiologic / methods. Radionuclide Imaging. Radiopharmaceuticals. Sarcoma / diagnostic imaging. Sarcoma / drug therapy. Sarcoma / radiotherapy. Uterine Cervical Neoplasms / diagnostic imaging. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1167-75 [15909196.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7445-53 [16157939.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1842-50 [7965167.001]
  • [Cites] J Nucl Med. 1993 May;34(5):773-9 [8478710.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):159-171 [14516540.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Thorac Surg. 2004 Jan;77(1):254-9; discussion 259 [14726072.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Head Neck. 2002 Feb;24(2):127-35 [11891942.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5928-34 [16115935.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2167-71 [15169804.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23 (33):8362-70 [16293866.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Cancer. 2002 Jun 15;94(12 ):3277-84 [12115361.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] J Clin Oncol. 1996 Mar;14 (3):700-8 [8622014.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] J Nucl Med. 2005 Sep;46(9):1481-7 [16157531.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1470-7 [7751894.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2797-803 [11387350.001]
  • [Cites] Radiology. 1995 Jul;196 (1):167-73 [7784562.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1352-61 [1696309.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9 [15573074.001]
  • [Cites] Radiology. 2003 Mar;226(3):906-10 [12616024.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Arch Neurol. 1989 Dec;46(12 ):1302-7 [2556096.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1806-14 [14602864.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Thorac Surg. 2002 Jan;73(1):259-64; discussion 264-6 [11834020.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):811-9 [14762698.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:4S-14S [14736831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):412-8 [15380574.001]
  • [Cites] Ann Thorac Surg. 2004 Dec;78(6):1903-9; discussion 1909 [15560998.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1776-85 [15386332.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):283-5 [11208816.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2651-7 [12860940.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5661-2 [16115898.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):97-106 [16397030.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1838-42 [15534052.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):530-41 [15297944.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10 ):1637-43 [10520703.001]
  • [Cites] J Nucl Med. 1999 Jul;40(7):1085-90 [10405124.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5117-25 [15955906.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):170-7 [12509971.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):300-9 [11224616.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):900-8 [14990646.001]
  • [Cites] Lung Cancer. 2002 Feb;35(2):179-87 [11804691.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):361-8 [11996465.001]
  • [Cites] Chest. 2001 Nov;120(5):1584-91 [11713138.001]
  • (PMID = 16688451.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 66
  •  go-up   go-down


7. Stettner N, Ranen E, Dank G, Lavy E, Aroch I, Harrus S, Brenner O, Harmelin A: Murine xenograft model of Spirocerca lupi-associated sarcoma. Comp Med; 2005 Dec;55(6):510-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Murine xenograft model of Spirocerca lupi-associated sarcoma.
  • Nodular masses and granulomas of the esophagus are among the most frequent lesions caused by Spirocerca lupi, a nematode parasite of dogs, and neoplastic transformation of these granulomas to osteosarcoma or fibrosarcoma has been described.
  • In this study, we developed a xenograft murine model of S. lupi-associated sarcoma.
  • Samples of esophageal fibrosarcoma and osteosarcomas were excised from three dogs diagnosed with spirocercosis.
  • These sarcomas were inoculated into three groups of 6-week-old NOD/SCID mice to create three tumor lines of S. lupi-associated sarcomas.
  • Mice in all groups developed tumors after inoculation, and the cell lines could be further propagated as second-generation xenografts.
  • We successfully established xenograft murine models of three different lines of S. lupi-associated sarcoma that offer readily available sources of these tumors for further experiments.
  • This resource will facilitate studies on the malignant transformation of the granulomas, establishment of efficient chemotherapy and radiotherapy regimens, and identification of diagnostic molecular markers.
  • [MeSH-major] Dog Diseases / parasitology. Models, Biological. Sarcoma / parasitology. Thelazioidea / metabolism. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422146.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, López Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, Pérez X, Germá-Lluch JR: Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol; 2008 Nov 20;26(33):5416-21
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.
  • PURPOSE: To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma.
  • Chemotherapy consisted of either four cycles of cisplatin and etoposide or three cycles of cisplatin, etoposide, and bleomycin.
  • After a median follow-up time of 71.5 months, six patients with stage IIB disease experienced relapse, and one of these patients died as a result of seminoma.
  • Three patients experienced non-seminoma-related deaths (two died from a further esophageal carcinoma, and one died from an upper digestive hemorrhage).
  • CONCLUSION: Chemotherapy is a highly effective and well-tolerated treatment for patients with stage IIA or IIB seminoma and represents an available alternative that could avoid some of the serious late effects associated with radiotherapy.
  • Further studies focusing on long-term toxicities of different treatment modalities are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Middle Aged. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):2101-2; author reply 2102-3 [19289608.001]
  • (PMID = 18936476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MF, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM: Clear cell sarcoma of the mediastinum. Ann Diagn Pathol; 2009 Jun;13(3):197-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of the mediastinum.
  • At thoracotomy, the mass was found tightly adherent to the esophageal wall and right lower lobe of the lung.
  • The diagnosis of clear cell sarcoma was supported by demonstrating the presence of an EWS gene rearrangement by fluorescence in situ hybridization.
  • To the best of our knowledge, primary mediastinal clear cell sarcoma has not been previously reported in the literature.
  • We present the case and discuss the differential diagnosis.
  • [MeSH-major] Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. RNA-Binding Protein EWS / genetics. Sarcoma, Clear Cell / genetics. Sarcoma, Clear Cell / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433300.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


10. Ranen E, Lavy E, Aizenberg I, Perl S, Harrus S: Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997-2003). Vet Parasitol; 2004 Jan 30;119(2-3):209-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997-2003).
  • Seventeen client-owned dogs diagnosed with spirocercosis-associated esophageal sarcomas were retrospectively reviewed.
  • Five of the cases that underwent PE also received chemotherapy after surgery (doxorubicin (Adriamycin, Upjohn)) with an average survival time of 267 days.
  • The histopathological results of the esophageal tumors were osteosarcoma (9), fibrosarcoma (5) and undifferentiated sarcoma (1).
  • In areas endemic to spirocercosis, regurgitation or vomiting in dogs and microcytic hypochromic anemia and neutrophilia warrant ruling out esophageal sarcomas.
  • Proper surgical treatment could prolong the dogs' lifespan for months, and improve their quality of life.
  • [MeSH-major] Dog Diseases / parasitology. Esophageal Neoplasms / parasitology. Esophageal Neoplasms / veterinary. Sarcoma / parasitology. Sarcoma / veterinary. Spirurida Infections / veterinary. Thelazioidea / growth & development
  • [MeSH-minor] Anemia, Hypochromic / pathology. Anemia, Hypochromic / veterinary. Animals. Dogs. Esophagectomy / veterinary. Female. Histocytochemistry. Leukocytosis / pathology. Leukocytosis / veterinary. Male. Radiography, Thoracic / veterinary. Retrospective Studies. Tomography, X-Ray Computed / veterinary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746980.001).
  • [ISSN] 0304-4017
  • [Journal-full-title] Veterinary parasitology
  • [ISO-abbreviation] Vet. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • Altogether, 4 of 13 patients (31%) had recurrence of the sarcoma after resection.
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • The deaths due to other causes included an esophageal cancer and a wound infection.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


12. Wang X, Wang S, Wang J: [Effect of gecko alcohol extract on human esophageal squamous carcinoma cell line EC9706 and anti-tumor activity in vivo]. Zhongguo Zhong Yao Za Zhi; 2010 Aug;35(16):2175-9
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of gecko alcohol extract on human esophageal squamous carcinoma cell line EC9706 and anti-tumor activity in vivo].
  • METHOD: in vitro, the inhibitory effect of gecko alcohol extract on proliferation of human esophageal carcinoma EC9706 cells was measured by MTT colorimetric assay.
  • The expression of apoptosis protein Bax and Bcl-2 in EC9706 cells was investigated by immunohistochemistry. in vivo, the inhibitory effect of gecko alcohol extract on tumor growth was examined on S180 sarcoma model.
  • RESULT: After gecko alcohol extract (6-8 g x L(-1)) treatment for 24, 48 and 72 h separately, EC9706 cell proliferation was significantly inhibited in both dose- and time- dependent manner (P < 0.01).
  • Gecko alcohol extract inhibited the growth of S180 sarcoma in Kun-ming mice at all doses (0.6, 1.2, 2.4 g x kg(-1)) of administration.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Ethanol / chemistry. Lizards / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Humans. Male. Medicine, Chinese Traditional / methods. Mice. Sarcoma / drug therapy. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046756.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / bcl-2-Associated X Protein; 3K9958V90M / Ethanol
  •  go-up   go-down


13. Shimizu K, Tanigawa K, Takeshita N, Aruga A, Mulé JJ, Takasaki K: A phase I trial of combination therapy of tumor lysate-pulsed dendritic cells and adoptive transfer of anti-CD3 activated T cells (TP-DC/CAT) in patients with advanced gastrointestinal (GI) cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):2585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of combination therapy of tumor lysate-pulsed dendritic cells and adoptive transfer of anti-CD3 activated T cells (TP-DC/CAT) in patients with advanced gastrointestinal (GI) cancers.
  • : 2585 Background: We have previously shown that tumor lysate-pulsed DC vaccination (TP-DC) elicited therapeutic rejection of established tumor in animal models.
  • In addition, combination of TP-DC with administration of activated T cells elicited more significant therapeutic rejection of established tumor than the single therapy alone in animal models.
  • We therefore sought to examine the therapeutic potency of TP-DC with administration of anti-CD3 activated T cells (CAT) against GI cancers: 3 pts were diagnosed with pancreatic cancer, 7 pts with HCC, 3 pts with intrahepatic cholangiocarcinoma, 2 pts with esophageal sarcoma, 12 pts with colorectal cancer.
  • ) 4 times every 3 weeks with 1 x 109 CAT activated with interleukin-2 and antibody to CD3: 4 pts received 1 x 106 DC, 7 received 2 x 107, 16 received 1 x 108.
  • Ten of these pts had evaluable unresected tumor resistant to conventional chemotherapy.
  • 13 of 16 pts receiving 1 x 108 DC developed a strong positive skin reaction to tumor lysates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Chasen MR, Eades M, Jelowicki M, Amdouni S, Sharma R: The McGill Cancer Nutrition and Rehabilitation Program. J Clin Oncol; 2009 May 20;27(15_suppl):9623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9623 Background: Cancer rehabilitation is a process that assists the individual with cancer to obtain optimal physical, social, psychological, and vocational functioning within the limits created by the disease and treatment.
  • The McGill Cancer Nutrition and Rehabilitation (CNR) program developed as a result of the ever-increasing demand to address the individual cancer patients and their needs, as well as on achieving optimal tumour-related outcomes.
  • All patients were evaluated with the Edmonton Symptom assessment Score (ESAS), Distress thermometer (DT), Patient Generated Subjective Global Assessment (PG-SGA), Simmonds Functional Assessment Tool and the 6-Minute Walk Test (6MWT).
  • Their cancer diagnoses were: gastro-esophageal (20%), hepatobiliary (19%), breast (17%), hematological (12%), lung, ENT and sarcoma (9% each), colorectal (3%) and CNS lymphoma (2%) There was a significant improvement after an 8-week cancer rehabilitation program in strength (p=.
  • 02), appetite (p< 0.001), nausea (p< =0.02), nervousness (p< 0.001) sleepiness (p=0.01), shortness of breath (p=0.02), depression (p< 0.001), DT (p< 0.001), total PG-SGA score (p< 0.001) and 6MWT (p=0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Stettner N, Ranen E, Dank G, Lavy E, Brenner O, Harmelin A: Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model. Comp Med; 2007 Jun;57(3):267-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model.
  • To date, data are not available concerning the effectiveness of chemotherapy in the treatment of Spirocerca lupi-associated esophageal sarcomas.
  • Tumor-bearing mice were divided into treatment and control groups.
  • The treatment groups were injected with either pegylated liposomal doxorubicin (6 mg/kg, intravenously, n = 9), doxorubicin (6 mg/kg, intravenously, n = 8), carboplatin (60 mg/kg, intraperitoneally, repeated twice at 1-wk intervals for a total of 2 doses, n = 9), or cisplatin (6 mg/kg, intraperitoneally, n = 8).
  • Our results indicate that doxorubicin-based drugs are effective against S. lupi-associated sarcomas in a mouse xenograft model.
  • Because it is less toxic than doxorubicin, pegylated liposomal doxorubicin is likely the drug of choice for treatment of S. lupi-associated sarcomas.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Dog Diseases / drug therapy. Osteosarcoma / drug therapy. Sarcoma, Experimental / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605341.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Chauvet B, de Rauglaudre G, Mineur L, Alfonsi M, Reboul F: [Dose-response relationship in radiotherapy: an evidence?]. Cancer Radiother; 2003 Nov;7 Suppl 1:8s-14s

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite many clinical datas, difficulties remain to demonstrate a relation between dose and local control: relative role of treatment associated with radiation therapy (surgery, chemotherapy, hormonal therapy), tumor heterogeneity, few prospective randomized studies, uncertainty of local control assessment.
  • Three different situations are discussed: tumors with high local control probabilities for which dose effect is demonstrated by randomized studies (breast cancer) or sound retrospective datas (soft tissues sarcomas), tumors with intermediate local control probabilities for which dose effect seems to be important according to retrospective studies and ongoing or published phase III trials (prostate cancer), tumors with low local control probabilities for which dose effect appears to be modest beyond standard doses, and inferior to the benefit of concurrent chemotherapy (lung and oesophageal cancer).
  • For head and neck tumors, the dose-response relationship has been explored through hyperfractionation and accelerated radiation therapy and a dose effect has been demonstrated but must be compared to the benefit of concurrent chemotherapy.
  • Last but not least, the development of conformal radiotherapy allow the exploration of the dose response relationship for tumors such as hepatocellular carcinomas traditionally excluded from the field of conventional radiation therapy.
  • In conclusion, the dose-response relationship remains a sound basis of radiation therapy for many tumors and is a parameter to take into account for further randomized studies.
  • [MeSH-minor] Adult. Breast Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / radiotherapy. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Prognosis. Prostatic Neoplasms / radiotherapy. Radiation Tolerance. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Retrospective Studies. Risk Factors. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15124539.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 41
  •  go-up   go-down


17. Ranen E, Dank G, Lavy E, Perl S, Lahav D, Orgad U: Oesophageal sarcomas in dogs: histological and clinical evaluation. Vet J; 2008 Oct;178(1):78-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumour types included osteosarcoma (47%), osteosarcoma with tumour giant cells (7%), fibroblastic osteosarcoma (13%), chondroblastic osteosarcoma (7%) fibrosarcoma (23%) and undifferentiated sarcoma (3%).
  • Histological grade evaluation revealed 33% grade 1 sarcoma, 50% grade 2 and 17% grade 3.
  • No correlation could be found between survival and signalment, duration of clinical signs, tumour type, tumour grade and chemotherapy.
  • Chemotherapy was found to reduce lung metastases' histological scores in three cases (P=0.0007).
  • Surgery seems to be the treatment of choice but the effect of chemotherapy warrants further investigation.
  • [MeSH-major] Dog Diseases / pathology. Esophageal Neoplasms / veterinary. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804268.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Yoshida S, Kaibara A, Ishibashi N, Shirouzu K: Glutamine supplementation in cancer patients. Nutrition; 2001 Sep;17(9):766-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Three series of studies investigated whether 1) glutamine deficiency occurs in tumor-bearing rats, 2) glutamine supplementation improves protein metabolism during chemotherapy in tumor-bearing rats, and 3) oral glutamine supplement improves systemic immune and gut-barrier function in patients with esophageal cancer receiving radiochemotherapy.
  • METHODS: In the animal studies, AH109A hepatoma cells or Yoshida sarcoma cells were inoculated into male Donryu rats to induce tumors.
  • In the clinical study, 13 patients with esophageal cancer were randomized into two groups, control and glutamine supplemented (30 g/d), for 4 wk.
  • Glutamine-supplemented total parenteral nutrition reduced whole-body protein breakdown rate during chemotherapy in tumor-bearing rats.
  • Oral supplementation of glutamine to the patients with esophageal cancer enhanced lymphocyte mitogenic function and reduced permeability of the gut during radiochemotherapy.
  • CONCLUSIONS: Glutamine depletion in host tissues occurs in tumor-bearing rats.
  • [MeSH-major] Cachexia / therapy. Esophageal Neoplasms / therapy. Glutamine / administration & dosage. Glutamine / metabolism. Proteins / metabolism
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbon Isotopes. Case-Control Studies. Combined Modality Therapy. Dietary Supplements. Disease Models, Animal. Humans. Male. Parenteral Nutrition, Total. Rats

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11527675.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Proteins; 0RH81L854J / Glutamine
  •  go-up   go-down


19. Brambilla AM, Castagna A, Nocita B, Hasson H, Boeri E, Veglia F, Lazzarin A: Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. J Acquir Immune Defic Syndr; 2001 May 1;27(1):44-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: The OIs occurring between June 1996 and December 1998 were retrospectively reviewed, considering only the episodes of major and minor OIs in patients with simultaneously available CD4 and plasma HIV RNA determinations before clinical onset who had been untreated or on stable antiretroviral therapy (ART) for at least 2 months.
  • Kaposi sarcoma, esophageal candidiasis, oropharyngeal candidiasis, and Mycobacterium avium complex disease were associated with significantly above-average median HIV RNA levels, and varicella-zoster virus infection was associated with below-average levels.
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. Humans. Retrospective Studies. Risk Factors


20. Goodman KA, Wolden SL, LaQuaglia MP, Alektiar K, D'Souza D, Zelefsky MJ: Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy; 2003;2(3):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The IOHDR dose was prescribed to a depth of 0.5 cm from the surface of a multichannel tissue-equivalent applicator.
  • The median prescription dose was 12 Gy (range, 4-15 Gy).
  • Late events that occurred in or near the IOHDR treatment site included small bowel obstruction, broncho-esophageal fistula, and bone growth retardation.
  • CONCLUSIONS: IOHDR is emerging as an integral part of multimodality therapy for pediatric solid tumors as an adjunct to EBRT for local control.
  • Subacute toxicities occurred rarely and may be related to the combination of extensive surgery, EBRT, and multi-agent chemotherapy in this population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Intraoperative Period. Male. Morbidity. Radiotherapy Dosage. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / radiotherapy. Sarcoma / surgery. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062136.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Maurel J, Zorrilla M, Puertolas T, Antón A, Herrero A, Artal A, Alonso V, Martinez-Trufero J, Puertas MM: Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs; 2001 Oct;12(9):713-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolonged infusion time may yield higher intracellular dFdCTP concentrations.
  • Twenty-seven patients (13 head and neck cancer, seven sarcoma, three esophageal cancer, three non-small-cell lung cancer and one ovarian cancer) were enrolled.
  • Twenty patients were defined as refractory at first- or second-line chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11593051.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


22. Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P: Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol; 2004 Jul;15(7):1123-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up to two previous chemotherapy regimens were allowed.
  • CONCLUSIONS: This pemetrexed-oxaliplatin combination (without vitamin supplementation) every 21 days can be administered using full therapeutic doses of each agent with acceptable tolerability and no overlapping toxicity.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205208.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 0 / Organoplatinum Compounds; 04Q9AIZ7NO / Pemetrexed; 04ZR38536J / oxaliplatin; 5Z93L87A1R / Guanine
  •  go-up   go-down


23. Blot E, Decaudin D, Veyradier A, Bardier A, Zagame OL, Pouillart P: Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency. Thromb Res; 2002 Apr 15;106(2):127-30
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A concomitant decrease of Ca 19-9 level and hemolysis was observed during chemotherapy, in parallel with normalization of Von Willebrand factor-cleaving protease activity.
  • [MeSH-major] Anemia, Hemolytic / etiology. Jaundice / etiology. Metalloendopeptidases / deficiency. Neoplasms, Radiation-Induced / complications. Paraneoplastic Syndromes / etiology. Sarcoma / complications. Thrombocytopenia / etiology. von Willebrand Factor / physiology
  • [MeSH-minor] ADAM Proteins. Adenocarcinoma / blood. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Breast Neoplasms / therapy. CA-19-9 Antigen / blood. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Esophageal Neoplasms / blood. Esophageal Neoplasms / surgery. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoplasms, Multiple Primary. Neoplasms, Second Primary / blood. Neoplasms, Second Primary / complications

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ltd.
  • (PMID = 12182911.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / von Willebrand Factor; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS13 protein, human; EC 3.4.24.- / Metalloendopeptidases; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


24. Kato Y: [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2240-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers].
  • We assessed the efficacy of WT1 peptide pulsed dendritic cell (DC) therapy for various advanced cancers.
  • All patients were vaccinated 5 times for 10 weeks with autologous monocytes derived DC and activated T lymphocytes.
  • We evaluated 20 of the 26 patients who finished 5-time vaccination (10 men and 10 women, aged 48-81 years, Mean 64 years) and were diagnosed as follows: 3-pancreas cancer, 2-colorectal, 2-breast, 2-esophageal, 2-lung, 2-uterus, 2-ovarian and 5 others.
  • Furthermore, the 7 PRs were resulted from 2-colorectal, and one of each was lung, laryngeal, axis, pancreas and smooth muscle sarcoma cancer.
  • The 4 of 7 PR patients were treated with chemotherapy.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Lymphocyte Activation. Neoplasms / therapy. T-Lymphocyte Subsets / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Dendritic Cells / immunology. Female. Humans. Immunotherapy, Active / methods. Male. Middle Aged. Picibanil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / WT1 Proteins; 39325-01-4 / Picibanil
  •  go-up   go-down


25. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets; 2005 May;5(3):171-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapy for gastrointestinal cancer.
  • Receptor and non-receptor tyrosine kinases (TKs) have emerged as clinically useful drug target molecules for treating gastrointestinal cancer.
  • Imatinib mesilate (STI-571, Gleevec(TM)), an inhibitior of bcr-abl TK, which was primarily designed to treat chronic myeloid leukemia is also an inhibitor of c-kit receptor TK, and is currently the drug of choice for the therapy of metastatic gastrointestinal stromal tumors (GISTs), which frequently express constitutively activated forms of the c-kit-receptor.
  • Gefitinib (ZD1839, Iressa(TM)) has been on trial for esophageal and colorectal cancer (CRC) and erlotinib (OSI-774, Tarceva(TM)) on trial for esophageal, colorectal, hepatocellular, and biliary carcinoma.
  • In addition, erlotinib has been evaluated in a Phase III study for the treatment of pancreatic cancer.
  • Cetuximab (IMC-C225, Erbitux(TM)), a monoclonal EGFR antibody, has been FDA approved for the therapy of irinotecan resistant colorectal cancer and has been tested for pancreatic cancer.
  • Bevacizumab (Avastin(TM)), a monoclonal antibody against VEGF, was efficient in two randomized clinical trials investigating the treatment of metastatic colorectal cancer.
  • It is also currently investigated for the therapy of pancreatic cancer in combination with gemcitabine.
  • Other promising new drugs currently under preclinical and clinical evaluation, are VEGFR2 inhibitor PTK787/ZK 222584, thalidomide, farnesyl transferase inhibitor R115777 (tipifarnib, Zarnestra(TM)), matrix metalloproteinase inhibitors, proteasome inhibitor bortezomib (Velcade(TM)), mammalian target of rapamycin (mTOR) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, platelet derived growth factor receptor (PDGF-R) inhibitors, protein kinase C (PKC) inhibitors, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitors, Rous sarcoma virus transforming oncogene (SRC) kinase inhibitors, histondeacetylase (HDAC) inhibitors, small hypoxia-inducible factor (HIF) inhibitors, aurora kinase inhibitors, hedgehog inhibitors, and TGF-beta signalling inhibitors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Gastrointestinal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Humans. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / drug effects. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Receptor, Epidermal Growth Factor / drug effects. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / metabolism. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892618.001).
  • [ISSN] 1568-0096
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 102
  •  go-up   go-down


26. Corti M, Villafañe MF: [The compromise of esophagus in HIV/AIDS diseases]. Acta Gastroenterol Latinoam; 2003;33(4):211-20
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The compromise of esophagus in HIV/AIDS diseases].
  • Esophageal disease is a common complication in patients infected with human immunodeficiency virus type-1 (HIV-1).
  • Dysphagia, odynophagia and retrosternal pain are the most common symptons associated with the esophageal compromise.
  • Esophageal candidiasis, the most frequent opportunistic infection, may occur in patients with long-standing infection or may be a manifestation of the seroconversion.
  • Cytomegalovirus and Herpes simplex virus are more likely to produce esophageal ulcers or erosions.
  • Neoplasms as Kaposi's sarcoma, are an infrequent cause of symptomatic disease.
  • Endoscopy may be warranted to make a rapid diagnosis such that specific therapy will not be delayed.
  • The use of a combination of histologic, cytologic, mycologic and virologic studies is necessary to provide an etiologic diagnosis of these lesions.
  • [MeSH-minor] Antifungal Agents / therapeutic use. Candidiasis / complications. Candidiasis / drug therapy. Cytomegalovirus Infections / complications. Esophagitis, Peptic / etiology. Herpes Simplex / complications. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14708474.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 92
  •  go-up   go-down


27. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


28. Williams G, Pazdur R, Temple R: Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat; 2004 Feb;14(1):5-21
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing tumor-related signs and symptoms to support cancer drug approval.
  • While prolongation of survival is an obvious end point for new cancer drug approval, the US Food and Drug Administration (FDA) has also utilized end points that evaluate patient symptoms.
  • In this article we discuss the end points, evidence, and analyses supporting cancer drug approvals based on evaluations of tumor-related signs and symptoms.
  • With advice from the Oncologic Drug Advisory Committee (ODAC) in the late 1970s and early 1980s, FDA determined that acceptable end points for cancer drug approval were survival or an improvement in the quality of a patient's life, e.g., an improvement in tumor-related symptoms.
  • This article summarizes 15 FDA cancer drug approvals based on patient symptom assessments and/or physical signs (thought to represent symptomatic improvement) as the primary evidence of effectiveness.
  • These include painful bone events (three cases), cosmetic improvement in Kaposi's sarcoma and cutaneous T-cell lymphoma (six cases), the consequences (decreased transfusions, etc.) of long-duration responses in leukemias and lymphomas (two cases), relief of pulmonary or esophageal obstruction (two cases), and one case each of symptom benefit in pancreatic cancer (also associated with survival benefit) and pulmonary symptom benefit in lung cancer.
  • An instructive example of an individual patient benefit end point is discussed, though it did not lead to a drug approval (the cisplatin-epinephrine gel application).
  • Improved trial designs and analysis plans may allow greater reliance on morbidity assessments to support future cancer drug approvals.
  • Drug sponsors are encouraged to include symptom assessments in cancer clinical trials and to perform further research to improve symptom-assessment methods.
  • The FDA routinely meets with sponsors at End of Phase 2 Meetings to discuss drug development plans and the design of phase 3 trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Approval / statistics & numerical data. Neoplasms / drug therapy. United States Food and Drug Administration / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15027497.001).
  • [ISSN] 1054-3406
  • [Journal-full-title] Journal of biopharmaceutical statistics
  • [ISO-abbreviation] J Biopharm Stat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 15
  •  go-up   go-down


29. Pollock J: Radiation-induced secondary malignancy of the esophagus. Ann Thorac Surg; 2001 Aug;72(2):669
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced secondary malignancy of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Sarcoma / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Humans. Risk. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Thorac Surg. 2000 Aug;70(2):660-2 [10969699.001]
  • (PMID = 11515938.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement